RT Journal Article
SR Electronic
T1 Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.25.24314885
DO 10.1101/2024.10.25.24314885
A1 Hall, Peter
A1 Williams, Matthew
A1 Peerani, Eleonora
A1 Tham, Elli
A1 Iori, Francesco
A1 de Fraine, George Richard Tiger Bevan
A1 Loughrey, Kerrie
A1 Kaffa, Andreas Dimitri
A1 Richardson, Thomas David Laurent
A1 Liberal, Carolina
A1 Velentza-Almpani, Angeliki
A1 Wiskerke, Demi Annemarie
A1 Sangkolah, Farah
A1 Crawley, Aston Martin
A1 Kearney, Jay
A1 Bah, Nourdine Kabirou
A1 Tasoulis, Marios Konstantinos
A1 Kirwan, Cliona C
A1 Cleator, Susan
A1 Chan, Steve
A1 Ranatunga, Duleek
YR 2024
UL http://medrxiv.org/content/early/2024/11/01/2024.10.25.24314885.abstract
AB Introduction: More than 150,000 women die worldwide every year of Triple-Negative Breast Cancer (TNBC). There are a range of treatment options, but no good way to match patients to their optimal treatment. For most newly diagnosed patients with early TNBC, the current standard of care is neoadjuvant chemo/immunotherapy before surgery, with patients who achieve a pathological complete response (pCR) having a better prognosis. We have developed a Functional Precision Medicine (FPM) test that uses a fresh biopsy, dissociates the cells, embeds them in a 3D hydrogel matrix, cultures them in a microfluidics device and tests them against a range of systemic therapies, while using a computer vision pipeline to measure responses to therapies ex vivo. Methods: We designed and conducted an observational multi-centre clinical trial to assess the feasibility of using our FPM assay in patients with newly diagnosed TNBC undergoing neoadjuvant therapy. Patients underwent an additional core needle biopsy followed by systemic therapy as part of routine care. We assessed the response in our assay against whether patients achieved pCR or not at the time of definitive surgery, and calculated Receiver-Operating Characteristic curves (ROC) to optimize cut-offs. In patients who did not achieve pCR, we explored whether there were other regimens that had a better in-assay performance. Results: In cohort A, we recruited 34 patients, of whom 12 are evaluable as of 31st July 2024 All were female. Nine patients achieved a pCR. Specificity was 100%, sensitivity 78%, p = 0.0455 and the AUC for the ROC for predicting pCR vs. non-pCR was 0.78. In the 3 patients who did not achieve a pCR, one patient had a regimen that performed better in assay than the treatment they received, and where the response was greater than the cut-off that predicted pCR in other patients. Conclusion: We have presented interim results from a novel FPM assay in patients with early stage TNBC. Our test demonstrates good performance in predicting pCR. The trial continues to accrue data, and Cohort B continues to recruit (PEAR-TNBC; NCT05435352).Competing Interest StatementWilliams, Peerani, Tham, Iori, de Fraine, Loughrey, Kaffa, Richardson, Liberal, Velentza-Almpani, Wiskerke, Sangkolah, Crawley, Kearney, Bah, Ranatunga are employees of Pear Bio, with salary, stock options and IP. Hall has received honoraria from Pfizer, Eisai, MSD, Seagen, Exact Sciences, Gilead, AstraZeneca and conference expenses from Lilly and Novartis. Tasoulis has received honoraria from the BMJ and Company: BMJ and IntegraConnect Kirwan reports no Conflict of Interest Clinical TrialNCT05435352Clinical Protocolshttps://www.clinicaltrials.gov/study/NCT05435352Funding StatementThis study was funded by Ourotech (trading as Pear Bio)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London Queen Square Research Ethics Committee gave ethical approval for this work. Reference: 21/PR/1027I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are not publicly available due to the sensitive commercial nature of the data